All In Biotech

Drug Trial Radar · NCT01356680

HD17 for Intermediate Stage Hodgkin Lymphoma

HD17 for Intermediate Stages - Treatment Optimization Trial in the First-Line Treatment of Intermediate Stage Hodgkin Lymphoma

Last checked: Nov 20, 2026Latest source record: Apr 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,100

Actual

Start

Jan 13, 2012

Primary completion

Mar 21, 2020

Study completion Mar 23, 2020

Sponsor

Lead sponsor
University of CologneAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 19, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of progression free survival (PFS).

Conditions

  • Hodgkin Lymphoma

Interventions

  • BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)Drug

  • ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)Drug

  • 30Gy IF-RT (Involved-Field Radiotherapy)Radiation

  • 30Gy IN-RT (Involved-Node Radiotherapy)Radiation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free SurvivalTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • 1st Dept. of Medicine, Cologne University Hospital

    Cologne, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.